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                           INTRODUCTION                          
                                          Chronic kidney disease (CKD) is becoming 
a major public health problem worldwide. The median prevalence of 
CKD was 7.2% in persons aged 30 years or older. In persons aged 
64 years or older prevalence of CKD varied from 23.4% to 
35.8%1.The prevalence of CKD in India is 0.8%, and diabetes has 
emerged as the most  frequent cause (30–40%)2  .It is estimated that 
1,00,000 new  patients of end stage renal disease (ESRD) enter renal  
replacement programs annually in India3 . 
                                               Chronic kidney disease (CKD) is 
associated with a high incidence of cardiovascular events.4 
Cardiovascular calcium deposition has been recognized as a 
common finding in patients with renal failure.5 . 
                                       Mitral annular calcification is a chronic, 
degenerative process of the mitral valve fibrous ring, involving the 
posterior annulus. It is a common disorder in the elderly, above all in 
women. It may also occur in younger patients with advanced renal 
disease or other metabolic disorders that result in abnormal calcium 
metabolism. CKD patients are exposed to a much greater risk for the 
calcification of cardiac valves and coronary arteries than the general 
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population.6 ,7MAC occurs earlier in patients with chronic renal failure 
than those without renal dysfunction  Mitral annulus calcification in 
the elderly is associated with a doubled risk of stroke, independent of 
the traditional risk factors. Each 1 mm increase in mitral annular 
calcification was associated with an increase in all-cause mortality of 
about 10 percent. 
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                   REVIEW OF LITERATURE 
       CHRONIC KIDNEY DISEASE 
                                        CKD is defined as kidney damage with or without 
decreased GFR, manifested as either pathologic abnormalities or 
markers of kidney damage, including abnormalities in composition of 
blood or urine, abnormality in renal imaging findings and a GFR less 
than 60 mL/min 1.73 m2 (8). The prevalence and the incidence of CKD 
are increasing. The most common causes of CKD leading to ESRD 
are diabetes mellitus, hypertension, glomerulonephritis, and cystic 
kidney disease, which together account for 90% of all new cases of 
CKD. Hypertensive nephropathy is a common cause of CKD in the 
elderly. Progressive nephrosclerosis from vascular disease is the 
renal correlate of the same processes that lead to coronary heart 
disease and cerebrovascular disease. 
                                      The increasing incidence of CKD in the 
elderly has been ascribed, to decreased mortality from the cardiac 
and cerebral complications of atherosclerotic vascular disease in 
them, enabling a greater segment of the population to manifest the 
renal component of generalized vascular disease. Majority of those 
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with early stages of renal disease, especially of vascular origin, will 
succumb to the cardiovascular and cerebrovascular consequences of 
the vascular disease before they can progress to the most advanced 
stages of CKD. Inter-individual variability in the rate of progression to 
CKD has an important heritable component, and a number of genetic 
loci that contribute to the progression of CKD have been identified. 
Similarly, it has been noted that women of reproductive age are 
relatively protected against progression of many renal diseases, and 
sex-specific responses to angiotensin II and its blockade have been 
identified.  
Pathophysiology of CKD 
                       It involves two broad sets of mechanisms of damage: 
(1) initiating mechanisms specific to underlying etiology like  immune 
complexes and mediators of inflammation in glomerulonephritis, or 
toxins in certain diseases of the renal tubules and interstitium;   and 
 (2) a set of progressive mechanisms, involving hyperfiltration and 
hypertrophy of the remaining viable nephrons, that are a common 
consequence following long-term reduction of renal mass. Increased 
intrarenal activity of the renin-angiotensin axis appears to contribute 
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both to the initial adaptive hyperfiltration and to the subsequent 
maladaptive hypertrophy and sclerosis.  
 
 
          Risk Factors for Chronic Kidney Disease 
 
    Established risk factors  
    Age 
    Gender (male predilection) 
    Race (African American, Native American) 
    High blood pressure 
    Diabetes mellitus 
    Obesity 
    Metabolic syndrome 
    Proteinuria 
    Family history of kidney disease 
    Smoking 
    Atherosclerosis 
    Exposure to nephrotoxins such as analgesics, heavy metals
    Dyslipidemia 
    Reduced nephron number at birth 
    Recurrent urinary tract infection   
    Emerging risk factors  
    Oxidative stress 
    Elevated plasma homocysteine level 
    Anemia 
    Prothrombotic factors (e.g., plasminogen inhibitor activator-1) 
 
 6
                 
            CAUSES OF CHRONIC RENAL FAILURE 9 
 
 
    Diabetic glomerulosclerosis  
    Hypertensive nephrosclerosis  
   
 Glomerular disease 
 
    Glomerulonephritis 
    Amyloidosis, light chain disease
   
 Systemic lupus erythematosus,
Wegener's granulomatosis 
  
   
 Tubulointerstitial disease 
 
    Reflux nephropathy (chronic pyelonephritis) 
    Analgesic nephropathy 
    Obstructive nephropathy (stones, benign prostatic hypertrophy) 
    Myeloma kidney   
   
 Vascular disease 
 
    Scleroderma 
    Vasculitis 
    Renovascular renal failure (ischemic nephropathy) 
    Atheroembolic renal disease   
   
 Cystic diseases 
 
    Autosomal dominant polycystic kidney disease 
    Medullary cystic kidney disease   
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                   STAGES OF CKD WITH THE  
             FREQUENCY OF COMPLICATIONS 
 
 
Stage 
 
Description 
 
GFR(mL/min/1.73 
m2) 
 
Symptoms or Signs
 
>90 Anemia 4% 
  Hypertension 40% 
1 Chronic kidney 
damage with normal 
or increased GFR   5-year mortality 19%
 
60–89 Anemia 4% 
  Hypertension 40% 
2  
 
Mild GFR loss   5-year mortality 19%
 
30–59 Anemia 7% 
  Hypertension 55% 
3  
Moderate GFR loss 
  5-year mortality 24%
 
15–29 Hyperphosphatemia 
20% 
  Anemia 29% 
  Hypertension 77% 
4  
 
Severe GFR loss 
  5-year mortality 46%
 
<15 or dialysis Hyperphosphatemia 
50% 
  Anemia 69% 
  Hypertension >75% 
5   
Kidney failure 
  ESRD 
 
  3-year mortality 14%
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                             CLINICAL  PRESENTATION  
                              Patients are asymptomatic in the early stages of 
CKD, most patients do not come to medical attention until most of 
their kidney function has been lost. Features of advanced CKD 
disease  include fatigue, anorexia, nausea, morning vomiting, 
malnutrition, pruritus, bone pain, impotence, amenorrhea, epistaxis, 
easy bruising, myopathy, muscle twitching and cramps, nail changes, 
uremic frost on skin surfaces, pleurisy, pericarditis, edema, volume 
overload, lethargy, confusion, asterixis, peripheral neuropathy, 
seizures, and coma. Hypertension and proteinuria are the most 
common features of CKD and are present at all stages of the disease.  
                                     Progressive metabolic acidosis develops 
when renal ammoniagenesis fails and impairs tubular acid excretion. 
If untreated, metabolic acidosis leads to osteodystrophy (through 
bone buffering), skeletal muscle breakdown, and diminished albumin 
synthesis. Gastrointestinal bleeding may occur secondary to platelet 
dysfunction and diffuse mucosal erosions through the gut. Uremia 
leads to impaired capillary permeability, fluid accumulation, and 
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uremic serositis, a syndrome characterized by pericarditis, pleural 
effusions, and ascites. 
                          Renal osteodystrophy results from secondary 
hyperparathyroidism (caused by hyperphosphatemia and 
hypocalcemia, marked parathyroid hypertrophy, and bony resistance 
to the action of parathyroid hormone) and metabolic acidosis. The 
principal types of bone disease in CKD are osteitis fibrosis (resulting 
mainly from secondary hyperparathyroidism) and adynamic bone 
disease (resulting from oversuppression of parathyroid hormone). 
                        In CKD  all organ systems are affected, but the most 
evident complications include anemia and associated easy fatigability; 
decreasing appetite with progressive malnutrition, abnormalities in 
calcium, phosphorus, and mineral-regulating hormones, such as 
1,25(OH)2D3 (calcitriol) and parathyroid hormone (PTH); and 
abnormalities in sodium, potassium, water, and acid-base 
homeostasis.  
                     The cause of anemia in patients with CKD can be 
multifactorial with a central component being a relative deficiency of 
erythropoietin  an erythrocyte-stimulating protein that is normally 
produced by renal parenchymal cells in response to blood partial 
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pressure of oxygen. Anemia caused by CKD is present in 20 percent 
of patients with stable coronary disease and 30 to 60 percent of 
patients with HF. Hence anemia is a common and easily identifiable 
potential diagnostic and therapeutic target 10,11 . 
                                              Hypertension, like anemia, is almost universal in 
CKD patients and often is the first sign of CKD. Hypertension 
contributes to the development of cardiovascular disease, the leading 
cause of morbidity and mortality in CKD patients. Hypertension in 
CKD patients is mainly the result of an expanded extracellular volume 
from a salt-rich diet and a decreased capacity for excretion of sodium. 
Another mechanism for hypertension in CKD patients is activation of 
the renin-angiotensin-aldosterone (RAA) system and the sympathetic 
nervous system. Evidence for activation of the RAA system in CKD 
patients includes circulating levels of renin and aldosterone that are 
too high for individuals who are hypertensive, suggesting that the 
vasoconstrictive action of angiotensin II and the salt retention induced 
by aldosterone contribute to hypertension. Patients with hypertension 
frequently have serum uric acid values in the upper range of normal 
or at supranormal levels and this  can cause vascular damage, 
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suggesting that uric acid could play a role in the genesis of 
hypertension in CKD. 
Evaluation 
                  Evaluation of CKD should include measurements of GFR 
and the degree of albuminuria. Most studies of cardiovascular 
outcomes have found that a critical cut point for the development of 
various adverse effects , is an eGFR of 60 ml/min/1.73 m2, which 
roughly corresponds to a serum creatinine greater than 1.5 mg/dl in 
the general population12, 13 Because Cr is a crude indicator of renal 
function and often underestimates renal dysfunction in women and 
the elderly, calculated measures of eGFR or Cr clearance using the 
Cockcroft-Gault equation or the Modification of Diet in Renal Disease 
equation are superior methods for the assessment of renal function.  
        
                                     The four-variable Modification of Diet in Renal 
Disease equation for eGFR is the preferred method because it does 
not rely on body weight 14     The equation for MDRD  is   
Estimated GFR (mL/min per 1.73 m2) = 1.86 x (PCr)–1.154 x (age)–0.203  
Multiply by 0.742 for women  and 1.21 for African Americans 
 
 12
    
      Cockcroft-Gault   equation  
              e GFR =(140-Age)× body weight in Kg  ÷  (72 × Cr in mg/dl) ,  
                       Multiply by 0.85 for women.   
                       Cr  means   serum creatinine. 
                                      Proteinuria is the most frequent early 
indicator of kidney damage. While an accurate 24-h urine collection is 
the "gold standard" for measurement of albuminuria, the 
measurement of albumin-to-creatinine ratio in a spot first-morning 
urine sample is often more practical to obtain and correlates 
well .Persistence in the urine of >17 mg of albumin per gram of 
creatinine in adult males and 25 mg albumin per gram of creatinine in 
adult females usually signifies chronic renal damage A recently 
approved blood test reflecting renal filtration function is the cystatin C 
test.15 Cystatin C is a nonglycosylated, low-molecular-mass (13 kDa) 
protein produced by all nucleated cells. Serum levels of cystatin C are 
independent of weight and height, muscle mass, age, and sex, 
making it less variable than Cr. 
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                  ASSESSMENT OF PROTEINURIA  
 
 
  Urine 
Collection 
Method 
Normal Microalbuminuria Albuminuria 
or Clinical 
Proteinuria 
Total 
protein    
 24-hour 
excretion  
   
 Spot urine 
protein/ 
creatinine 
ratio   
   < 300 mg/day  
   < 200 mg/g   
   NA  
   NA   
    > 300 mg/day  
    > 200 mg/g   
Albumin 
    24-hour excretion  
   
 Spot 
albumin- 
specific 
dipstick   
   < 30 mg/day  
   < 3 mg/dl   
  30–300 mg/day 
  > 3 mg/dl   
    > 300 mg/day  
    NA   
  
Spot urine 
albumin/ 
creatinine 
ratio 
 
 
 
   
< 17 
mg/g 
(men)  
   
< 25 
mg/g 
(women)  
  17–250 mg/g (men)  
  25–355 mg/g (women)   
   
 > 250 
mg/g 
(men)  
   
 > 355 
mg/g 
(women)  
 
                                       Markers of kidney damage other than 
proteinuria include abnormalities in the urine sediment and 
abnormalities on imaging studies.   Urine sediment examination or 
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dipstick for red blood cells and white blood cells should be performed 
in all patients with CKD.     Imaging of the kidneys should be  
 performed in all patients with CKD to evaluate for structural 
abnormalities, impaired renal blood flow, and urinary obstruction. 
Imaging should begin with renal ultrasonography but may also 
include computed tomography or magnetic resonance imaging.  
 
Calcium and Phosphate metabolism in CKD 
                                         Normal serum levels of phosphorus and 
calcium are maintained through the interaction of two hormones: 
parathyroid hormone (PTH) and 1,25(OH)2D (calcitriol). These 
hormones act on three primary target organs: bone, kidney, and 
intestine. The kidneys play a critical role in the regulation of normal 
serum calcium and phosphorus concentrations, thus derangements 
are common in patients with chronic kidney disease (CKD). 
Abnormalities are initially observed in patients with glomerular 
filtration rate (GFR) levels less than 60 mL/min and are nearly 
uniform at a GFR less than 30 mL/min.  
                                        Chronic kidney disease (CKD) is associated 
with a number of important disturbances in mineral metabolism, 
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which include hypocalcemia, hyperphosphatemia, and abnormalities 
in vitamin D metabolism that result in functional calcitriol 
deficiency.16Elevated plasma levels of parathyroid hormone (PTH), a 
key calcium-regulating hormone that also affects renal phosphorus 
excretion, and fibroblast growth factor 23, a recently identified 
phosphorus-regulating hormone, occur often.17,18 The major 
consequences of disordered mineral metabolism in CKD are 
secondary hyperparathyroidism, metabolic bone disease, and extra 
skeletal calcification.19,20  
                        Studies have demonstrated that the serum 
phosphorus and the calcium × phosphorus product are associated 
with poor outcomes in CKD. The association of elevated serum 
phosphorus and mortality has been confirmed in several studies. 
Block and colleagues used a large dialysis data base of more than 
40,000 patients undergoing hemodialysis in the United States and 
found an association with increased mortality for phosphorus levels 
greater than 5.0 mg/dL, with a progressive increase in mortality with 
increasing levels.21 In this same study, the relative risk of death 
correlated directly to serum calcium levels, increasing 47% as the 
calcium level increased from 9 to 9.5 mg/dL to more than 11 mg/dL.. 
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                      Epidemiologic studies have revealed the major cause of 
death in the presence of hyperphosphatemia and hypercalcemia to 
be cardiovascular events.22 Studies have demonstrated an 
association of hyperphosphatemia with increased vascular stiffening, 
arterial calcification and calciphylaxis and valvular calcification.23  
                    VASCULAR CALCIFICATION IN CKD 
                        There is  high prevalence of vascular calcification in 
patients with CKD. Calcium can be deposited into either the medial or 
intimal layers of the vasculature. Calcium deposition in the medial 
layer, a common finding in dialysis patients, is associated with 
stiffening of the vasculature, resulting in significantly adverse 
cardiovascular outcomes. Intimal calcium deposition is principally 
associated with atherosclerotic plaques; in patients with normal renal 
function, such "complex" plaques are more often associated with 
myocardial infarction and thrombotic events. Compared to those with 
intimal calcification, patients with medial disease had a longer 
survival. However, survival was less than that observed in those 
without calcification 
                            There is  evidence for increased arterial calcification 
in coronary, renal, and iliac arteries from patients on dialysis 
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compared with nondialysis patients. Braun and associates24 
demonstrated that coronary artery calcification is  increased with 
advancing age in patients on dialysis and that the calcification scores 
were two to five fold greater in dialysis patients than age-matched 
individuals with normal kidney function and angiographically proven 
coronary artery disease. More recent data in patients not yet on 
dialysis also demonstrates an increased risk of coronary artery 
calcification, especially in diabetic patients25. Nearly 50% to 60% of 
patients starting hemodialysis have evidence of coronary artery 
calcification26. The only risk factors for coronary artery calcification 
that are uniform across studies are advancing age and duration of 
dialysis. Several "modifiable and nonmodifiable" factors that are able 
to promote vascular calcification are extremely frequent in patients 
with CKD. Most of the present strategies to decrease vascular 
calcifications are based in the control of the more prevalent 
modifiable risk factors. Unfortunately, the extremely important 
nonmodifiable risk factors, which are highly prevalent, such as older 
age, time on dialysis, and diabetes, are not under one's control. 27  
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                    Pathophysiology 
Vascular calcification is a tightly regulated process that resembles 
mineralization in bone.28Vascular calcification in arteries from ESKD 
patients is associated with expression of bone matrix proteins and the 
osteoblast differentiation factor core binding factor alpha-1 (Cbfa1)29 
now called RUNX-2. Runx-2 is thought to be the transcription factor 
that switches a pluripotent mesenchymal stem cell to the 
chondrocyte- osteoblast lineage, because animals deficient in RUNX-
2 fail to mineralize bone30. Non RUNX-2 pathways such as MSX may 
also be stimulated by bone morphogenic proteins31 Several 
nontraditional CKD cardiovascular risk factors can accelerate 
vascular calcification, including PTH and PTH-related peptide, 
calcitriol, advanced glycation end products, alterations of lipoproteins, 
and homocysteine.28 
 Inhibitors of Vascular Calcification 
                                                    Vascular calcification, although very 
prevalent in dialysis patients, is not uniform in all. Depending on the 
series, an average of 17% of dialysis patients have no vascular 
calcification, and continue to not have calcification on follow up.27,32. 
Younger age is partially responsible for the protection against 
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calcification and  also  the presence of naturally occurring inhibitors of 
calcification. Matrix gla protein (MGP) is a vitamin K-dependent 
protein expressed in a number of tissues but highly expressed in  
arteries and bone, where it acts predominantly as a local regulator of 
vascular calcification. The mechanism by which MGP inhibits 
extraskeletal calcification appears to be through binding to BMP-2 or 
modulation of BMP-2 activity, because BMP-2 is known to induce 
vascular calcification33. MGP activity is inhibited by warfarin and in 
dialysis patients, warfarin is associated with calciphylaxis.34. OPG 
(osteoprotegerin) is another  direct inhibitor of vascular calcification 
but there  is conflicting data about this in CKD patients. 
                        Another potential inhibitor of extraskeletal calcification 
is fetuin-A (α2-HS glycoprotein). Fetuin-A inhibits the de novo 
formation and precipitation of the apatite precursor mineral basic 
calcium phosphate but does not dissolve it once the basic calcium 
phosphate is formed.35. Another naturally occurring inhibitor of 
mineralization is pyrophosphate. The precise role of these and other 
inhibitors in the vascular calcification in patients with CKD remains to 
be determined, but clearly, there are multiple mechanisms to regulate 
extraskeletal calcification. 
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 Potential Mechanisms of -Vascular Calcification in CKD 
                               There are several different, but not mutually 
exclusive, mechanisms by which disturbances in mineral and bone 
metabolism may lead to or accelerate vascular calcification. In the 
past, a calcium × phosphorus product of 70 mg2/dl2 was considered 
the threshold above which  metastatic calcification occurred.Now 
values more than 56 mg2 /dl2 is considered as significant. 
                                Elevations in calcium, phosphorus, and the 
calcium × phosphorus product can increase extraskeletal calcification 
by both passive precipitation and by direct effect on vascular smooth 
muscle cells. Calcium-based phosphate binders  also play role in the 
pathogenesis of vascular calcification. In treat-to-goal study36 
calcification was  increased in the calcium-binder treatment arm, 
whereas there was no increase in the sevelamer(phosphate binder) 
arm. Another therapy that may increase vascular calcification is 
vitamin D therapy37 but not clearly linked to vascular calcification in 
patients with end stage  CKD. 
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                      CARDIOVASCULAR DISEASE AND CKD 
                                             Patients with kidney failure are at high 
risk of cardiovascular mortality38. They  experience a high rate of fatal 
and nonfatal cardiovascular disease events prior to reaching kidney 
failure39,40. Patients in all stages of CKD are therefore considered in 
the “highest risk group” for development of cardiovascular disease 
and CKD is recognized as a cardiovascular risk equivalent1,42. CKD is 
a risk factor for cardiovascular disease and cardiovascular disease 
may be a risk factor for CKD. Analysis of community-based studies 
including Atherosclerosis Risk in Communities Study, Cooperative 
Health Study, Framingham Heart Study, and the Framingham 
Offspring Study, CKD defined as GFR of 15 to 60 ml/min/1.73 m2, 
was an independent predictor of a composite outcome of all-cause 
mortality as well as fatal and nonfatal cardiovascular disease events43. 
Several studies has established urinary albumin excretion as an 
independent predictor of cardiovascular outcomes44 in CKD patients. 
                                                 Patients with CKD are much more likely to suffer 
from atherosclerosis and heart failure, resulting in cardiovascular 
death, than to eventually require renal replacement therapy. This is 
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likely due in part to accelerated rates of cardiovascular disease 
among those with CKD. In addition, patients with CKD are more likely 
to present with atypical symptoms, which may delay diagnosis and 
adversely affect outcomes. Traditional cardiovascular risk factors, 
such as hypertension smoking history, diabetes mellitus, dyslipidemia 
and older age, are highly prevalent in CKD populations45,46. Patients 
with CKD are also more likely to have the metabolic syndrome, which 
could contribute to the increase in cardiovascular risk47,48. Increased 
arterial stiffness is noted in patients with CKD is also a possible risk 
factor .Some risk factors  are relatively unique to patients with 
moderate to severe CKD. These include retention of uremic toxins, 
anemia, increased calcium intake, abnormalities in bone mineral 
metabolism, and  proteinuria.  
                                   The overall absolute risk of future adverse 
cardiovascular events is somewhat lower with CKD patients than that 
observed in patients with a history of prior heart disease, but without 
CKD. In general, the risk is approximately 50 percent lower with CKD 
alone, although the risk increases with increasing renal dysfunction 
and/or severity of proteinuria. All patients with the same degree of 
renal dysfunction also do not have the same risk of cardiovascular 
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disease. Thus, in addition to the evaluation for the presence of CKD, 
the proper assessment of overall cardiovascular risk requires an 
adequate assessment for the presence and severity of the other 
major risk factors for cardiovascular disease 
 
        Most common causes of death among patients with CKD49 
 
 
 
 
 
            
 
                          ISCHEMIC HEART DISEASE 
                                     Ischemic heart disease most commonly 
results from atherosclerosis of the coronary arteries. The processes 
that contribute to accelerate atherosclerosis include a dyslipidemia 
characterized by decreased function of lipoprotein lipase, reduced 
HDL-C, elevated TG, and elevated LDL-C. Both uremia and dialysis 
therapy markedly enhance oxidant stress through the production of 
proinflammatory complement fragments, cytokines, and increased 
Heart failure 31.2% 
Myocardial infarction 15.6% 
Sepsis 11.3% 
Withdrawal from dialysis 5.2% 
Strokes 6.4% 
Malignant neoplasm 3.8% 
Other 26.5% 
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adhesion molecules in endothelial cells50. Endothelial dysfunction 
begets cardiac and arterial remodeling with resultant cardiovascular 
events. Potentially important in the inflammatory cascade and 
ensuing cardiovascular mortality among kidney patients are C-
reactive protein (CRP) and asymmetric dimethyl-arginine. 
 
                                 HEART FAILURE 
                                    About 40% of people starting dialysis therapy 
have a history of heart failure symptoms, which is a risk factor for 
significant morbidity and mortality in this group51. For those without 
heart failure symptoms at the commencement of dialysis, 25% will 
develop it within 3½ years (7% per year)52. Age (risk increased by 
30% for every 10 years), female sex, hypertension, diabetes, 
conditions of atherosclerosis (CAD, cerebrovascular or peripheral 
vascular disease), pericarditis, and structural cardiac abnormalities 
(left ventricular hypertrophy, clinical cardiomegaly) were all 
associated with heart failure. Multiple studies of patients with class II 
and III HF, in whom a low cardiac output state is not present, have 
shown decreased survival in a graded fashion related to renal 
impairment. 
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                          VALVULAR HEART DISEASE 
                               Impaired renal function has been linked to 
valvular calcification and aortic sclerosis. Advanced thickening of the 
cardiac valves and calcification have been observed in patients with 
ESRD53. Bacterial endocarditis may develop in patients with ESRD 
who have temporary dialysis access catheters.  Most valvular lesions 
observed in patients with CKD are acquired and develop from 
dystrophic calcifications of the valvular annulus and leaflets, 
particularly the aortic and mitral valves. Such calcification is now 
known to be present far more frequently than previously recognized 
with a prevalence of up to 55% and 39% for the aortic and mitral 
valves respectively54,55. Once considered benign, aortic valve 
sclerosis is now also associated with an increased cardiovascular 
mortality in the general community. 
 
                  MITRAL ANNULAR CALCIFICATION 
                                      Mitral annular calcification is commonly seen 
in association with aging and in patients with renal failure. Incidence 
is more common in females. The calcium begins to form in or below 
the mitral annulus at the junction between the ventricular myocardium 
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and the posterior mitral leaflet. More severe degrees of calcification 
will form a pattern resembling the letter J, the letter O, or a reversed 
letter C . In most instances, mitral annulus calcification has little 
clinical significance and is a noninflammatory chronic degenerative 
process. In extreme cases, the mass of calcification can grow 
posteriorly into the ventricular myocardium to produce heart block. It 
can also grow anteriorly into the leaflets of the mitral valve to cause 
mitral regurgitation and stenosis. Rarely, the calcification can erode 
through the endocardium and cause small systemic emboli. Mitral 
annulus calcification in the elderly is associated with a doubled risk of 
stroke, independent of the traditional risk factors. 
                                         Two large observational series showed that MAC 
was present in 8 percent of subjects with a mean age of 5756 and 48 
percent of subjects with a mean age of 81 57. MAC is associated with 
atherosclerosis, thromboembolic events (including stroke) and, in 
some series, atrioventricular conduction defects 58,59. Patients with 
MAC may also have calcification of the aortic annulus, aortic valve, 
aortic root, sinotubular junction, papillary muscle tips, and systemic 
calcified atherosclerosis. In an electron beam CT study, MAC was 
significantly associated with calcific atherosclerosis in the ascending 
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and thoracic aorta and the carotid arteries, but not the coronary or 
iliac arteries 58. Mitral annular calcification  is infrequently associated 
with hemodynamically important mitral insufficiency, mitral stenosis, 
or endocarditis 60,61. 
                                                      MAC, like calcific aortic valve disease, is 
associated with standard cardiovascular risk factors. However, Kizer 
et al62 recently showed that the presence of MAC but not of aortic 
valve sclerosis was a strong risk factor for incident stroke in a cohort 
of American Indians without clinical cardiovascular disease after 
extensive adjustment for other predictors. 
                                   A lesser known variant of MAC, is caseous 
calcification of the mitral annulus.  It is  described as “a round mass 
with a central echolucent area composed of a puttylike admixture of 
fatty acids, cholesterol, and calcium”63 . This variant of MAC carries a 
benign prognosis; however, it is important that it not be mistaken for a 
cardiac tumor 64,65. 
                    The echocardiographic appearance of MAC is 
characteristic and easily recognized. In the long axis view, it appears 
as a bright reflection most commonly in the posterior atrioventricular 
groove, which shadows objects behind it. As the severity of 
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calcification increases, the mass appears to grow into the 
myocardium of the left ventricular base and its inflow tract. Unless 
care is exercised, the process may be mistaken for posterior leaflet 
calcification because the mass and its ultrasonic side lobe artifacts 
obscure that relatively short structure. In the short axis view, careful 
angulation will reveal its typical C-shaped morphology and its location 
between the papillary muscles, from four to eight o'clock.  
          
                     Mitral annular calcification in CKD 
                                    Mitral annular calcification (MAC) occurs in 10 
to 50 percent of patients with end-stage renal disease 66,67.It is 
associated with an elevated calcium-phosphorus product, vascular 
calcification, hypercalcemia, and hyperphosphatemia. MAC occurs 
earlier in patients with chronic renal failure than those without renal 
dysfunction. In one study, MAC was more common in younger (less 
than 60 years of age) than older dialysis patients 67. Since older 
dialysis patients are commonly dialyzed for fewer years because of a 
marked increase in mortality, MAC appears to occur more frequently 
in those dialyzed for a longer period of time. 
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                          AIMS AND OBJECTIVE 
 
 
1  To  study  the prevalence of mitral annular calcification in chronic 
kidney disease patients compared to people with normal kidney 
function 
2.  To  find out various parameters  that shows significant  association 
with mitral annular calcification in chronic kidney disease patients 
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                    MATERIALS AND METHODS 
 
 
 Setting                              : Department of Medicine ,  
                                            Govt Rajaji hospital  Madurai 
 
 Design                              : case control  study 
 
 Period of study                 : six  months  study  
 
 Ethical approval               : Obtained from ethical committee approval  
                                            headed  by Dean, Govt. Rajaji hospital 
 Consent                            : Informed consent obtained from  
                                                   all  patients 
 Study population              : Patients attending outpatient  
                                              department or wards  with 
                                              chronic kidney disease  
Control group                     :Persons comparable in age and sex  
                                            with study group without kidney disease 
Collaborating                     : Department of Cardiology 
   Departments                     Department of  Nephrology 
Financial support               :  Nil 
Conflict of interest              : Nil 
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            SELECTION AND DETAILS OF STUDY SUBJECTS 
                             In the study group ,102 chronic kidney disease 
patients who attended the outpatient department or wards of 
Government Rajaji Hospital Madurai, fulfilling the inclusion criteria 
were selected randomly. Informed consent was obtained from all.  
Inclusion criteria 
             eGFR< 60 ml/min/1.73m2. 
             Documented elevated renal parameters for > 3 months. 
       …  Ultrasonography suggestive of chronic kidney disease. 
Exclusion criteria 
             eGFR > 60 ml /min/1.73m2. 
             Patients who underwent renal transplant. 
             Patients with valvular heart disease  of other causes. 
             Duration of disease  less than 3 months. 
             Patients with obstructive uropathy. 
             Patients not given consent. 
 
  
 32
                          The control group of 100  persons comparable to 
study group in age and sex distribution  and not having kidney 
disease ,were selected and evaluated.  
Data collection 
                     Profoma containing details regarding age, sex, history of 
diabetes mellitus, hypertension, coronary  artery 
disease ,cerebrovascular disease ,vital data and blood investigation 
and imaging studies were  filled up for all participants. 
                                   Participants who were receiving oral 
hypoglycemic drugs or insulin and those who had fasting glucose 
level >126mg/dl or postprandial glucose level > 200mg/dl were 
defined as diabetic. 
            Hypertension was defined as participants having 
                          systolic blood pressure  > 140 mm of Hg or 
                          diastolic bloodpressure  >  90 mm of Hg or 
                          those receiving medication for hypertension 
              An average of at least two readings of blood pressure were 
taken in all participants. 
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   Kidney function assessment 
              kidney function assessment  was estimated by GFR using  
Cockcroft-Gault   equation 
            e GFR =(140-Age) × body weight in Kg  ÷  (72 × Cr in mg/dl). 
  ,             Multiply by 0.85 for women.   
                Cr  means  serum creatinine. 
                                 In this study  definition of CKD was based on the 
National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative working group definition of CKD as a GFR < 60 ml/min per 
1.73 m2 . 
 
Echocardiographic Evaluation 
                           All the participants in study were subjected to 
echocardiographic evaluation (using Philips IE 33). Mitral annular 
calcification  was considered present when an echo-dense band was 
visualized in the region of the mitral annulus that was >0.3 cm thick 
on the M-mode or when the two -dimensional study demonstrated 
calcification  of more than one third of the circumference of the 
 34
annulus in the parasternal short-axis view .For all determinations of 
valvular calcification, interpreters confirmed visualization in more than 
one view. 
 
ULTRASONOGRAPHY  
              Ultrasonographic  evaluation of all  participants in the study 
were done to assess the presence of chronic kidney disease  based 
on following parameters (1) increase in cortical eccogenicity  (2) loss 
of corticomedullary differentiation ( 3) and contracted kidney . 
 
BIOCHEMICAL EVALUATION  
                                           All  the participants were evaluated for 
haemoglobin ,blood urea, serum creatinine , calcium, phosphorus, 
and potassium based on standard tests available in our hospital. 
Presence of albuminuria was also done in all participants. 
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                           RESULTS AND OBSERVATIONS 
CHARACTERISTICS  OF CASES AND CONTROL GROUPS 
SEX DISTRIBUTION    
                                 Table. 1  sex distribution 
 
                               Chi Square test: p Value=0.663 
 
                          Among 102 patients included in study , 63 (61.8% ) 
were males and 39 (38.2 %) were females .In control group 65 % 
were males and 35 % were females( p value = 0.663 ) and the two 
groups were comparable  
   AGE DISTRIBUTION 
          Both groups had  similar age distribution and were 
comparable    (P value 0.9 - Not significant) 
                    
 
 
Study Group 
 
       Control Group 
  
Female 
 
Male Total Female Male 
 
Total 
No  39 63 102 35 65 100 
% 38.2 61.8 100.0 35.0 65.0 100.0 
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                            Table.2        Age distribution 
Group 
 Study 
Group 
Control 
Group 
Total 
No 23 24 47 
<40 YRS 
% 22.5% 24.0% 23.3% 
No 56 56 112 
40-60 YRS 
% 54.9% 56.0% 55.4% 
No 23 20 43 
Age 
 
group 
>60 YRS 
% 22.5% 20.0% 21.3% 
No 102 100 202 Total 
% 100.0% 100.0% 100.0% 
 
                                Chi Square test: p Value=0.9 
 
 
Table.3       Diabetic status 
 
 
 Study Group 
 
Control 
Group 
Total 
 
 
No 76 79 155 
Non diabetic 
% 74.5% 79.0% 76.7% 
No 26 21 47 
Diabetic 
% 25.5% 21.0% 23.3% 
No 102 100 202 
 
% 100.0% 100.0% 100.0% 
 
                               Chi Square test: p Value=0.507 
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                  In study group 26 ( 25.5%) were diabetic and in control 
group 21 (21%) were diabetic  and there was no significant difference. 
 
                                        Table. 4    
                                       Hypertension 
 
    Study 
Group 
 
   Control         
Group 
 
     Total  
 
    No      18        80      98        
       Non-
Hypertensive    %       17.6%      80.0%     48.5% 
    No       84       20     104  
Hypertensive 
    %       82.4%      20.0%      51.5% 
  Total  No      102       100      202 
 
                                               
                                      Chi Square test: p Value < 0.001*** 
             In the study group 84 (82.4%) were hypertensive  compared  
20% in control group. P value < 0.001  shows  that hypertension was 
significantly high in chronic kidney disease patients. 
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                                                 Table.5           
                                  Coronary Artery Disease  
 
 
                               
                            Chi Square test: p Value=0.913 
                  
                     Coronary artery disease was present  in 20 ( 19.6%) 
among study group . In control group 19 (19 %)  had CAD. ( P value 
0.93  not significant) 
 
       Albuminuria 
 
                         Albuminuria  was present in 74 (72.5%) in study group 
and in control group only 8% had albuminuria. 
 
 
 Study Group
 
Control 
Group 
Total 
 
No 82 81 163  
No CAD    % 80.4% 81.0% 80.7% 
No 20 19 39  
CAD   
present % 19.6% 19.0% 19.3% 
 Total 102 100 202 
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                                               Table. 6           
                                              Albuminuria      
 
 
 Study Group 
 
Control Group 
 
Total 
 
 
No 28 92 120  
No   
Albuminuria % 27.5% 92.0% 59.4% 
No 74 8 82  
Albuminuria % 72.5% 8.0% 40.6% 
 Total 102 100 202 
  
                                 Chi Square test: p Value < 0.001*** 
 
        OTHER PARAMETERS  
                             In this study mean age is 51.35 and 49. 3 years in 
study and control groups respectively.  Hemoglobin and calcium 
levels were significantly ( p value <  0.001) low in study group  when 
compared to control group. Mean hemoglobin and calcium  levels 
were 8.3 gm % and 8.6 mg/ dl  in  study group and 11.7 gm % and 
9.42 mg /dl in control group respectively. 
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                  Table. 7     Characteristics of two groups 
 
 
            Dialysis in study group 
                 Among 102 patients in study group  37 (36.3 %)  were  on 
hemodialysis and  65 ( 63.7 % )  were   not undergone dialysis. 
 
                                         
 
Parameters 
 
Group 
Mean 
 
 
 
Std. 
Deviation 
 
 
Independent 
T-test(p 
Value) 
Study Gp 51.35 11.750 
Age (yrs) 
Control Gp 49.73 11.688 
0.326 
Study Gp 8.380 1.8093 Hemoglobin 
(gm %) Control Gp 11.797 1.7222 
0.000*** 
Study Gp 125.31 46.482 Blood Sugar 
(mg /dl) Control Gp 101.64 17.774 
0.000*** 
Study Gp 8.60 .796 Sr Calcium 
(mg/dl) Control Gp 9.42 .575 
0.000*** 
Study Gp 4.852 .6161 Sr Potassium 
(Mmol/L) Control Gp 4.218 .4024 
0.000*** 
Study Gp 57.02 8.151 
Weight(kgs) 
Control Gp 61.94 6.279 
0.000*** 
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                                         Table. 8   
                                     Dialysis  status 
 
                                               Table. 9  
                      MITRAL  ANNULAR  CALCIFICATION 
 
                               Chi Square test: p Value=0.010** 
                                In the study group 10 (9.8 %) among 102 patients 
had mitral annular calcification .In the control group only  1 ( 1% ) had 
mitral annular  calcification .p value is significant. 
 
       No.        % 
Not on  Dialysis 65 63.7 
Dialysis done 37 36.3  
Study Group 
Total 102 100.0 
ECHO cardiogram 
MAC  absent 
 
MAC  present 
  
No. 
 
% 
 
No. 
 
% 
 
Study Group 92 90.2% 10 9.8% 
Control Group 99 99.0% 1 1.0% 
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                                            Table. 10 
                              MAC  in various eGFR groups 
           
 
                              
                             Chi Square test: p Value=0.293 
 
 
               Among  10 patients who had  MAC  in study group,7 ( 70 % )  
were in the group with eGFR  < 15 ml/min  and  3 ( 30 % )  were in 
group with eGFR  15 to 30 ml/min.P value is  0.29 and not significant. 
Calcification was not present in the group with eGFR  30 to 60ml/min.   
 
ECHO 
 MAC 
present 
 
MAC 
absent 
 
Total 
 
No 46 7 53  
<15 
ml/min % 50.0% 70.0% 52.0% 
No 30 3 33  
15-30 
ml/min % 32.6% 30.0% 32.4% 
No 16 0 16 
CKD 
 
Stage 
 
30-60 
ml/min % 17.4%    0% 15.7% 
No 92 10 102  
Total % 100.0% 100.0% 100.0% 
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                                              Table.  11 
                                    MAC   age distribution 
                                 
ECHO cardiogram 
 MAC 
absent 
MAC 
present 
Total 
No 23 0 23 
<40 YRS 
% 25.0% 0% 22.5% 
No 50 6 56 
40-60 YRS 
% 54.3% 60.0% 54.9% 
No 19 4 23 
Age 
group 
>60 YRS 
% 20.7% 40.0% 22.5% 
No 92 10 102 
Total 
% 100.0% 100.0% 100.0% 
 
                         Chi Square test: p Value 0.048 
Among  10 calcification observed, 60 % were in age group 40 to 60 
years and 40 % in above 60 years. 
                         In the control group only 1 ( 1% )  calcification 
observed was in age group  above 60 years. 
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                                          Table .12 
                  Association of MAC  with various parameters 
                                       
 No  
Mean 
 
Std. 
Deviation 
 
T test 
(p value) 
 
MAC - 92 50.67 11.941  
Age (yrs) 
 MAC + 10 57.60 7.706 
 
.077 
MAC - 92 5.704 3.7193 Creatinine 
( mg/dl) 
 MAC + 10 5.180 1.7637 
 
.449 
MAC - 92 8.336 1.8367 Hemoglobin 
( gm % ) 
 MAC + 10 8.790 1.5560 
 
.454 
 
MAC  - 92 8.54 .771 Sr Calcium 
( mg / dl) 
 MAC + 10 9.16 .842 
 
.018** 
MAC - 92 4.839 .6228 Potassium 
(mmol/L ) 
 MAC + 10 4.970 .5658 
 
0.526 
MAC - 92 4.6489 .46303 Phosphorous 
(mg/ dl) 
 MAC + 10 5.5200 .27809 
 
0.000*** 
MAC - 92 39.5653 4.53871 Ca X Po4 
(mg2/dl2 ) 
 
MAC + 10 50.4560 4.34803 
 
0.000*** 
 
               P value is significant for  association with serum calcium , 
phosphorus and calcium phosphorus product . 
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                                               Table.13 
                          
                                        MAC and diabetes                
 
 
                           Chi Square test:   p Value=0.118 
Among 10 patients having MAC  50 % were diabetic. p value is not 
significant. 
 
                MAC   sex  distribution 
             Among 10 calcification in CKD patients, 5 were in males and 
5 were in females showing no significant sex predilection. 
 
 
 
 MAC  - 
 
MAC   + 
 
Total 
 
No 71 5 76 
 
Non-diabetic 
% 77.2% 50.0% 74.5% 
No 21 5 26 
 
Diabetic 
% 22.8% 50.0% 25.5% 
No 92 10 102 
 
Total 
% 100.0% 100.0% 100.0% 
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                                            Table.14   
                                     MAC and dialysis 
                               
                              Chi Square test: p Value=0.796 
 
                 In the study 3.9% of dialysed patients and 5.9 % of non 
dialysed patients had mitral annular calcification. P value is 0.79 and 
not significant. 
 
 
 
 
  
ECHO cardiogram 
 
MAC- MAC+ 
N 59 6 
% 64.1% 60.0% 
 
 
Not Dialysed 
% of Total 57.8% 5.9% 
N 33 4 
% 35.9% 40.0% 
 
 
Dialysed 
% of Total 32.4% 3.9% 
N 92 10 
% 100.0% 100.0% 
 
 
Total 
% of Total 90.2% 9.8% 
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                                               Table.15  
                                         CAD and MAC 
 
ECHO cardiogram 
 
MAC absent MAC present 
N 79 3  
CAD Absent % 85.9% 30.0% 
N 13 7  
CAD present % 14.1% 70.0% 
N 92 10  
Total % 100.0% 100.0% 
 
                           Chi square Test: p Value< 0.001**** 
 
                          In  CKD  patients with MAC  70 % had coronary 
artery disease compared to 14.1 % in patient not having MAC .  
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                              DISCUSSION 
                              In India  the approximate prevalence of CKD is 
800 per million population (pmp) and the incidence of end-stage renal 
disease (ESRD) is 150-200 pmp68.MAC occurs earlier in patients with 
chronic kidney disease than those without renal dysfunction and  is 
associated with atherosclerosis and  thromboembolic events 
(including stroke). 
                      In this study  , the main aim was  to find out the 
prevalence of mitral annular calcification in patients with chronic 
kidney disease  as compared  to those with out chronic kidney 
disease.  Beyond that association of mitral annular calcification with 
various parameters like  age , sex , diabetic status ,serum calcium , 
serum phosphorus , calcium  x  phosphorus product , estimated GFR 
and dialysis were  also observed . 
                       Among 102 patients who were allotted to study group 
63 (61.8 %) were males and 39 (38. 2 %) were females. In the control 
group 65 % were males and 35 % were  females.  
                  In the study group 26 % were diabetic while 21 % in 
control group. Prevalence of hypertension and coronary artery 
disease  were 82.4 %  and 19.6 % in study group and 20 %  and   
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19 % in control group respectively. Albuminuria was present in 72.5 
% of patients with CKD. 
               The two groups were comparable in age and sex  
distribution .CKD group had significant anemia ( mean Hb 8.3 gm%) 
compared to control group( mean Hb 11.7 gm %) P value < 0. 001. 
Calcium level was also significantly low in CKD group ( mean 8.6 
mg/dl) than control group (mean 9.42). Potassium level was high in 
CKD patients (4.85 mmol/L) compared to non CKD group(4.2 mmol/L)  
p value< 0.001. Anemia , hypocalcemia and hyperkalemia are well 
documented features of chronic kidney disease  . 
                     Mitral annular calcification was present in 9.8 % of 
patients with chronic kidney disease  while  only  1% had calcification 
in non CKD group; which shows that there is significantly high 
prevalence of MAC in CKD patients ( p valve 0.010) . In Framingham 
heart study69 on  “Association of kidney function with valvular and 
annular calcification”, prevalence of mitral annular calcification were  
12 % and 3 % in CKD and non CKD groups respectively. In 
“Atherosclerotic Risk in Communities study”, the overall prevalence of 
MAC was 4.6% for women and 5.6% for men.70 In participants aged 
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70 years and older, the prevalence of MAC was 10% in women and 
15.2% in men.70  
                      In this study , CKD patients with MAC, 70%  had    
eGFR  < 15 ml / min/1.73m2 and 30 % had  between 15 to 30 
ml/min/1.73m2. There is no significant  difference in MAC among 
various eGFR groups( p value 0.293). In a Study by Folkert W. 
Asselbergs & Dariush Mozaffarian, the prevalence of MAC were 
significantly high in individuals with  eGFR < 45 mL/ min/1.73 m2 (P < 
0.01). 
                      This study showed in CKD patients MAC was present in 
60% and 40% in age group 40 to 60 years and obove 60 years 
respectively. No calcification was found  in age group below 40 ( p 
value  0.048). In non CKD group calcification was present  only in 
above 60 age group .Usually MAC can be seen in elderly individuals. 
In CKD patients it is more prevalent and also occur in younger age 
group. 
           This study shows significant association between mitrall 
annular calcification in CKD patients with high serum levels  of 
calcium, phosphorus and calcium x phosphorus product. Mean serum 
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calcium level in CKD patients with MAC (9.16mg/dl) was significantly 
high compared to patients without MAC (8.54mg/dl) P value 0.018. 
Serum phosphorus in MAC group (5.5 mg/dl) also was significantly 
higher than CKD patients without MAC(4.6mg/dl) p < 0.001. Mean 
Calcium x phosphorus product in CKD patients with MAC 
(50.4mg2/dl2 ) was significantly higher than CKD patients without 
MAC (39.5mg2/dl2)  P value < 0.001. 
                           In study done by Maher ER, Young G71 MAC 
showed association with increased calcium X phosphorus product 
and long-term hemodialysis in CKD patients. Study done by Ribeiro S, 
Ramos et al 72showed positive correlation between age and Ca x P 
product with cardiac valvular calcification. This study states that in 
dialysis patients age and calcium phosphorus product as the most 
predictive parameters for valvular calcification 
                      This study does not show any significant association 
between mitral calcification and diabetic status (P value 0.118). 
Association between MAC and gender  also was insignificant .  
                     This study does not show significant increase in mitral 
calcification in chronic kidney disease patient who were on 
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dialysis .Various studies have shown that  presence of MAC  
increases with duration of dialysis. Disparity may be due to that, 
many of the dialysis group patients in this study, were not on regular 
dialysis and duration of dialysis was not taken into account. In Study  
by Yusuf and Selcoki Faruk, longer duration of dialysis was 
associated with mitral valve calcification. 
                                             This study showed significantly high 
association of coronary artery disease in CKD patients with mitral 
calcification than those with out calcification. 70 % of those with MAC 
had CAD compared to 14.1% in CKD patients without MAC ( P < 
0.001).The   study by  Fox CS, Vasan RS et al 73 showed  
independent association of MAC with incident CAD and CAD death 
and  suggest  cardiac calcification as a marker of increased CAD risk. 
The association between MAC, and increased cardiovascular risk 
may also be due to the burden of shared risk factors, including age, 
hypertension, hyperlipidemia, diabetes, and obesity. 
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                                       CONCLUSION 
1 The prevalence of mitral annular calcification in chronic kidney 
disease patients was 9.8% compared to 1% in  people with normal 
kidney function. 
2 Mitral annular calcification showed significant association with high 
serum calcium , phosphorus and calcium x phosphorus product in 
CKD patients. 
3 No significant association was noticed between  diabetes , dialysis 
status and gender with mitral annular  calcification.  
4.Mitral annular  calcification occurs at an earlier age in CKD patients.  
5 Coronary artery disease was significantly high in patients with mitral 
annular  calcification. 
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                                 SUMMARY 
                A case control study was conducted on prevalence of 
MAC in chronic kidney disease patients compared to subjects with 
normal kidney function. After obtaining ethical committee clearance , 
102  CKD patients  and 100 non CKD subjects comparable in age 
and sex distribution were selected randomly. After recording  clinical 
data, blood investigations and ultrasonographic study, 
echocardiogram was done in all to look for MAC 
               Results on analysis showed significantly high MAC in CKD 
patients. Among 102 CKD patients 10(9.8%) had MAC while only 
one(1%)  had MAC in non CKD group. Among 10 who had MAC in 
CKD group, 6 (60%) were in 40 to 60 age group and 4 (40%) were in 
above 60 age group. In non CKD group MAC was present only in an 
elderly female. In CKD patients MAC occurs even in younger age 
group. Significant association of high levels of calcium, phosphorus 
and calcium x phosphorus product with MAC was also noticed in the 
study. Increased MAC in CKD patients may be due to altered calcium 
and phosphorus metabolism in them. CAD was significantly high in 
those with MAC which may be due to the burden of shared risk 
factors for atherosclerosis in both groups. 
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NO AGE SEX DM HTN CAD CVA Hb RBS UREA Cr Ca K P Ca x P Ur. Alb Weight eGFR Echo USG DIALYSIS
1 75 F - + + - 6.1 138 94 4.3 8 4.5 5 40 + 52 9.56 N CKD ND
2 42 M - + - 9 86 46 1.4 9 4.2 4 36 - 60 58 N CKD ND
3 44 M - + - - 6.4 125 179 16.5 7.8 6 5.2 40.56 + 62 5 N CKD D
4 33 M - - - - 5.9 120 40 1.8 8.4 3.2 3.9 32.76 - 64 52.8 N CKD ND
5 20 M - + - - 10 80 109 9.6 7.5 4.4 4 30 + 58 10 N CKD D
6 31 M - + - - 5.7 74 74 7.2 8 6 4.5 36 + 52 10.9 N CKD ND
7 63 M - + + - 9.3 184 40 6 9.9 4.8 5.8 57.4 + 48 8.5 C CKD D
8 28 F - + - - 4.3 100 30 8.5 9.1 5.2 4.4 40.04 + 55 16 N CKD ND
9 61 F - + + - 5 240 150 9 8.1 6.4 5 40.5 + 61 7.4 N CKD ND
10 33 F - + - - 7.1 120 130 7.8 8.8 6 5.1 44.88 + 48 7.7 N CKD D
11 50 M - + - - 7.3 170 60 7 8.6 4.9 4.5 38.7 + 62 11 N CKD ND
12 51 F - + - - 5.6 90 70 6.5 9 5.3 4.2 37.8 + 70 13.3 N CKD D
13 61 M + + + - 10 99 70 7.4 10 5.4 5 50 + 65 9.6 C CKD ND
14 30 M + + - - 10 120 100 14 9.2 5.5 5 46 + 60 6.5 N CKD ND
15 55 F - + - - 11 90 40 1.8 8.7 5 4.1 35.67 + 50 27.8 N CKD ND
16 45 F - + - - 8 110 113 11.1 7.9 4.8 4.6 36.3 + 74 8.79 N CKD ND
17 54 M - + - - 12 120 30 4.2 8.2 4.1 4 32.8 + 66 17 N CKD ND
18 40 M - + - - 7 71 83 9 8.8 5.6 5 44 + 57 8.8 N CKD D
19 55 F + + - - 6.4 142 42 4.2 8 5.7 4.3 34.4 + 60 16.8 N CKD ND
20 29 F - + - - 8.5 125 100 7.7 7.5 4.1 4.6 34.5 + 64 12.8 N CKD ND
21 45 M - + + - 10 300 79 6 9.5 4.6 5.4 51.3 + 85 18.6 C CKD D
22 64 M - - + - 9.4 140 60 2.7 9.2 5 4.8 44.16 + 60 23.4 N CKD ND
23 59 M - + - - 9 110 110 9 9 3.5 5 45 + 55 6.9 N CKD ND
24 30 M - + - - 6 120 140 15 8.6 4.2 5.1 43.86 + 60 6.1 N CKD D
25 53 M - + - - 7 200 79 3.8 9 5 4.5 40.5 + 58 18.44 N CKD ND
26 49 M - + - - 8.4 64 61 7.4 8.7 5.2 4 34.8 + 68 11.6 N CKD ND
27 59 M + + - + 8 169 64 8 8.5 5.6 4.8 40.8 + 48 6.75 N CKD ND
28 48 F + + + - 7.8 90 40 4.3 8.8 4.2 5.3 46.64 + 50 12.6 C CKD D
29 68 F - + - - 7 130 89 5 8.5 5.3 4.2 35.7 + 54 9.1 N CKD ND
30 58 M - + - + 5.4 80 170 17 7 4.8 4.1 28.7 + 60 4 N CKD D
31 45 M - - - - 6 90 120 10 7.4 5.4 5.2 38.4 + 50 6.5 N CKD ND
32 45 F - + - - 11 110 38 2 8.3 4 4.6 38.18 - 54 30.2 N CKD ND
33 54 F + + 7.7 160 66 10 8 5.4 5 40 + 60 7.1 N CKD D
34 48 M - - - - 8.7 90 80 11 8.2 5.4 4.8 39.3 + 74 8.5 N CKD D
35 54 M + + - + 7 104 74 8 9.5 4.8 4.6 43.7 + 60 8.9 N CKD ND
36 65 F - + - - 9 110 140 7 7.2 5.5 4.5 32.4 + 58 8.6 N CKD D
37 64 M - + - - 6 92 64 6 8.5 5 4.3 36.55 - 60 10.5 N CKD ND
38 57 F + + - - 7.5 98 80 4.2 7.4 5.2 6 44.4 + 45 12.3 C CKD ND
39 28 F - - - - 5 90 30 4.5 8.1 5 4.6 37.2 - 56 16.45 N CKD ND
40 64 M - + + - 7.2 200 60 4 7.8 5.2 4 31.2 - 50 15.8 N CKD ND
41 65 F + + - - 6 133 120 8 6.1 5 5.3 32.33 + 55 6.08 N CKD D
42 45 F + + - - 8 110 90 8.6 7.5 4.5 5 37.5 + 68 10.4 N CKD ND
43 60 F - - - - 10 100 116 10 7 4 5.1 35.7 + 60 5.66 N CKD ND
44 63 M - + - - 10 100 200 9.8 7.5 3.5 5.5 41.25 + 54 5.8 N CKD D
45 27 M - + - - 9 95 180 18 7 6 5 35 + 60 5.2 N CKD ND
46 47 M + - - + 8 260 78 2.3 8.5 5 4.8 40.8 - 55 30.88 N CKD ND
47 59 M - + - - 9 220 100 4 8 4.8 4.5 36 - 68 19.1 N CKD D
48 60 F + - - - 8 170 80 3.4 8.5 4 4.2 35.7 + 70 19.44 N CKD ND
49 52 F + + + - 8.6 90 67 2.7 9 4.2 4.8 43.2 - 65 25.1 N CKD ND
50 52 M - + - - 8 110 80 4 7.8 5 4.8 37.44 + 70 21.3 N CKD D
NO AGE SEX DM HTN CAD CVA Hb% RBS Urea Cr Ca K P Ca xP Ur. Alb WEIGHT eGFR ECHO USG DIALYSIS
51 50 F - + - - 7.5 120 100 9.3 7 4.6 5 35 + 55 7.39 N CKD ND
52 56 M + + - - 8 180 130 9 7.1 4.8 4.8 34.08 + 80 10.3 N CKD D
53 47 M - - - - 10 110 74 4 9 5 4.9 44.1 - 70 22.6 N CKD ND
54 56 M - + - - 10 76 60 2 9.4 5 5 47 - 50 30 N CKD ND
55 40 M - + - - 9 90 50 3.9 8.6 4.8 5.1 43.8 + 45 16 N CKD D
56 52 M - - - - 8 104 90 2 8.5 4.5 4.4 37.4 + 47 28.7 N CKD ND
57 60 F + + + - 6.2 210 140 7 9 5.5 5.4 48.6 + 55 7.8 C CKD ND
58 40 M - - - - 7 120 60 1.9 9.5 4 4 38 - 60 43.8 N CKD D
59 62 M + + - - 9.2 190 90 5 9.3 5.4 4.1 38.1 + 65 14 N CKD ND
60 71 M - + - - 10 64 100 2.4 8 4.2 4.2 33.6 + 52 20.7 N CKD ND
61 50 F + - - 8.6 96 110 3 9.1 4.8 4.7 42.77 - 54 19.1 N CKD D
62 50 M - - + - 7 100 104 5.1 8.8 5.2 4.8 42.24 - 50 12.25 N CKD ND
63 42 M + - - 10 110 120 6 8.4 4.8 5 42 + 65 13 N CKD ND
64 50 M - + - - 11.2 86 60 1.8 9.8 4 4.2 41.1 - 55 38 N CKD D
65 60 F - - - - 6.3 80 80 2.7 9.5 5.1 4 38 + 50 17.4 N CKD ND
66 43 F + + - - 9 280 110 4 9 4.5 5 45 + 42 14.1 N CKD ND
67 38 M - - - - 8 90 78 2.1 8.8 4.6 4 35.2 - 62 41.8 N CKD D
68 60 M - + + - 11 160 180 7.1 8.7 5.8 5.6 48.72 + 50 7.2 C CKD D
69 55 M + - + - 7 190 90 11.2 8 5.2 4.5 36 - 50 52 N CKD ND
70 40 F - + - - 6.2 110 110 3.2 8.2 4 4.8 39.3 - 45 16.6 N CKD D
71 57 F + + - - 9 160 210 9 7.8 6 6 46.8 + 48 6.1 N CKD ND
72 70 M - + + + 10 140 78 2.3 10 5.4 5.5 55 - 52 21.9 C CKD ND
73 60 M - + + - 8 126 90 3 9 4.5 4.8 43.2 + 45 16.6 N CKD ND
74 65 F - - - - 7.4 108 65 1.9 9.4 4 5 47 + 60 27.9 N CKD D
75 40 F + + - - 9 210 94 2.7 9.1 4.7 4.5 40.95 - 44 19.2 N CKD ND
76 60 M + + - - 8 170 160 7.2 8 5.6 5.2 41.6 + 48 7.4 N CKD ND
77 66 F - + - - 10 96 104 3.5 9.4 5 5 47 + 58 17 N CKD D
78 68 M - + - - 10 120 140 7.8 8 5.7 5.8 46.4 + 55 7 N CKD D
79 70 F - + - + 4 90 110 4.2 8.9 5 4.8 42.72 + 47 9.24 N CKD ND
80 35 F - - - - 12 120 90 1.9 10 4 4 40 - 62 35.3 N CKD D
81 60 M + + - - 11 220 140 5 8.2 4.8 4.6 37.72 + 50 11.1 N CKD ND
82 48 M - + - - 9.6 100 118 2.2 9.3 4.5 4.8 44.6 - 57 33.1 N CKD D
83 55 F - + - - 8 90 134 2.7 9.5 4.4 4.3 40.85 + 54 20.06 N CKD D
84 62 F - + - - 9 84 180 4.3 9.8 4.2 5.7 55.8 + 46 9.85 C CKD ND
85 70 M - + + - 10 100 120 3 9 5.1 5.2 46.8 - 48 11.5 N CKD ND
86 62 M + + - - 11 140 200 6 8.1 5 5.7 44.3 + 52 9.38 N CKD ND
87 59 M + + - - 7.2 140 80 6 10 5.5 5 50 + 50 9.3 N CKD D
88 44 M - + - - 10 88 74 1.7 9.6 3.8 4 38.4 - 60 47.05 N CKD ND
89 52 M - + - - 8 90 96 3 8.8 4 3.9 34.32 - 58 23.6 N CKD D
90 48 M - + + - 10 100 96 5.4 8.6 5.5 4.3 36.98 + 50 11.8 N CKD ND
91 40 M - + - - 6 110 110 2.5 9.1 4.8 4.7 42.77 + 58 32.2 N CKD D
92 50 F + + - - 7.1 104 150 3.2 8.5 4.6 5.5 46.7 + 47 15.6 C CKD ND
93 64 F - + - - 8 130 110 4 8.6 4.5 4.7 40.42 + 55 14.5 N CKD D
94 60 M - + - - 10 96 88 2.2 9.3 4.8 4.3 39.99 - 51 25.75 N CKD ND
95 40 M - + - - 11 130 80 2.5 9.6 5 5 48 + 55 30 N CKD D
96 38 M - - - - 11.5 124 70 2 9.8 4.6 4 39.2 - 60 42.2 N CKD ND
97 40 M - + + 10 148 110 4.5 8.9 5 4.8 42.72 + 66 20.3 N CKD ND
98 65 F - + - + 8 80 95 3 9.1 4.8 5 45.5 + 55 16.23 N CKD ND
99 38 M - + + - 10 98 85 2.5 9 5 4.1 36.9 + 65 36.8 N CKD D
100 58 F - + - - 9 120 75 4.5 8.5 4.7 4.2 35.7 + 50 10.75 N CKD ND
101 40 M + + + + 9 110 114 4 8.8 4.2 4 35.2 - 60 20.8 N CKD ND
102 45 M - + - - 12.5 135 120 5.5 9 5 5 45 + 70 16.79 N CKD ND
NO AGE SEX DM HTN CAD CVA Hb RBS Ur Cr Ca K P Ca x  P Ur alb Weight Egfr Echo USG DIALYSIS
1 54 M - - - - 13 80 24 0.8 9 4 3.2 28.8 - 55 82 N N ND
2 41 M - + - - 12.5 110 20 0.7 9.5 4.2 3.4 32.3 - 45 88 N N ND
3 38 F + - + - 12 88 22 1 10 4.5 3 30 + 55 67 N N ND
4 28 M - - - - 14 90 18 1.2 10.2 3.8 4 40.8 - 60 77.7 N N ND
5 58 M - + + - 13 118 24 1.2 8.8 5 3.5 30.8 - 65 65 N N ND
6 51 F - - - - 10 120 30 1 9 4.8 2.9 26.1 - 65 76 N N ND
7 48 M - - - - 12 84 28 1.1 9.5 4.4 3 28.5 - 58 68 N N ND
8 41 F - - - - 12.5 90 30 1 10 4 3.5 35 - 55 64 N N ND
9 34 M - - - - 15 110 20 1.2 8.9 3.8 3.5 31.15 - 68 83 N N ND
10 65 M + - + + 13 114 22 0.9 11 5 4 44 - 70 81 N N ND
11 49 M - - - - 12 78 26 0.8 10.3 3.6 3 30.9 - 68 107 N N ND
12 62 M - + - - 11.5 64 18 1 9.6 4 2.5 24 - 75 81 N N ND
13 58 F + - - - 9 130 22 0.8 8.6 4.2 2.6 22.3 + 50 61 N N ND
14 28 M - - - - 14 86 16 1.2 10 4.3 3 30 - 55 71.2 N N ND
15 44 M - - - - 13 90 20 1.1 10.5 4 3.2 33.6 - 60 72.7 N N ND
16 68 F - - - + 11 120 18 0.9 9 4.6 2.9 26.1 - 70 66 N N ND
17 58 M + - + - 12 128 20 0.8 8.8 4.4 3.5 30.8 - 55 78.2 N N ND
18 53 M - + - - 13 80 22 0.9 9 5 3.8 34.2 - 50 67 N N ND
19 39 F - - - - 12 98 18 0.8 10 3.6 3 30 - 50 74.5 N N ND
20 38 M - - - - 15 88 24 1 8.6 4 3 25.8 - 65 92 N N ND
21 41 M - - + - 14 108 20 1.2 9.3 4.6 2.5 23.25 - 70 80.2 N N ND
22 68 M - + - - 13.5 76 24 1 9 5 2.8 25.2 - 65 65 N N ND
23 54 M - - - - 13 80 18 0.9 10.2 5.1 2.7 27.5 - 60 79.6 N N ND
24 65 F - - - + 11 92 28 1 9.5 3.5 3 28.5 - 65 62 N N ND
25 39 M - - + - 13 100 24 0.8 8.8 4 2.6 22.88 - 70 120 N N ND
26 48 M + - - - 13.5 90 20 1 10 4.5 3 30 - 50 64 N N ND
27 55 F - + - - 10 88 24 1 10.3 4.8 3.1 31.9 - 65 65.2 N N ND
28 43 F - - - - 8 140 28 1.1 9.5 4 3.2 30.4 - 70 64 N N ND
29 30 M - - - - 13 106 20 0.8 9.6 4.2 3 28.8 - 60 114 N N ND
30 70 F - - + - 9 110 36 0.8 10.4 4.8 2.8 29.1 - 72 74.3 N N ND
31 59 M - + - - 11 78 24 1 10 4 3 30 - 63 70 N N ND
32 55 F - - - - 8 90 30 1.2 9 4.8 3.5 31.5 - 68 66.8 N N ND
33 45 M + - + - 11.5 100 26 1.1 8.8 4 4 35.2 + 60 71.9 N N ND
34 59 F - + - - 10 108 28 0.9 9.6 4.3 3.6 34.5 - 64 80 N N ND
35 60 M - - - - 12 98 28 1 10.1 4.1 3 30.3 - 69 65.1 N N ND
36 38 M - - - - 13 130 20 0.9 9.2 4.2 3.6 33.1 - 63 99.1 N N ND
37 52 M + - - - 10 104 26 0.8 8.6 4.5 3 25.8 - 55 84 N N ND
38 36 F - - - - 13 78 18 1 8.2 4 3.1 25.4 - 58 73.6 N N ND
39 65 F - - - - 11 80 26 1.1 9.5 3.8 4.1 38.9 - 75 60.3 N N ND
40 36 M - - - - 14 114 16 1 10 4 4 40 - 48 69 N N ND
41 42 F + - - - 11.5 128 20 0.8 9.6 3.5 3 28.8 - 68 98 N N ND
42 62 F - + - - 12 150 36 0.8 10.1 5 3.5 35.35 - 65 75 N N ND
43 36 M - - - - 13.5 90 18 1 9.5 3.8 3.6 34.2 - 60 86 N N ND
44 72 F + - - - 8 100 30 0.9 8.9 4.2 4.3 38.27 - 70 62 N N ND
45 53 F - - - - 10 88 24 1 9.4 4 4 37.6 - 60 62 N N ND
46 28 F - - - - 12 118 16 0.7 10 4.5 2.9 29 - 58 109.5 N N ND
47 55 M + - + - 10 86 20 1 9.8 5 3 29.4 - 60 70.8 N N ND
48 68 F + - - - 11 90 26 0.9 10.4 3.5 4 41.6 - 72 68 C N ND
49 48 F - - - - 7 88 25 1 10 4.6 3.1 31 - 70 76 N N ND
50 54 M - + + - 12.5 96 28 1 8.8 4.4 3 26.4 - 60 71.6 N N ND
NO AGE SEX DM HTN CAD CVA Hb RBS UREA CREATININE Ca POTASSIUM P Ca x P Ur. Albumin Weight Egfr Echo USG DIALYSIS
51 42 M - - - - 12 90 18 1 9 4 3.8 34.2 - 60 81 N N ND
52 55 M - - + - 11 78 20 1.1 9.2 4.5 4 36.8 - 58 62 N N ND
53 35 M - - - - 12 80 22 0.8 10 4.6 2.8 28 - 70 125 N N ND
54 44 M + - - - 11 110 16 0.9 9.6 3.8 3.5 33.6 + 65 96 N N ND
55 52 F - - - - 13 120 26 1 9.5 5 3.4 32.3 - 68 70 N N ND
56 28 M - - - - 10 90 20 0.9 8.8 4.1 2.5 22 - 65 112 N N ND
57 62 M - - - - 11 96 28 1 9 3.9 4.1 36.9 - 58 63 N N ND
58 48 M + - + - 12 88 30 0.9 8.6 3.8 4 34.4 - 60 76 N N ND
59 58 M - + - - 13 78 18 0.8 10.1 4 4.1 41.41 - 62 88 N N ND
60 36 M - - - - 14.5 120 20 0.9 9.8 4.2 3 29.4 - 65 104 N N ND
61 65 M - - - + 12 108 22 1 9.6 4.2 3.7 35.52 - 65 67.7 N N ND
62 44 M - - + - 12.4 98 26 1 9 4.6 3 27 - 63 84 N N ND
63 48 F + - - - 9 88 18 0.9 10 4.8 4 40 - 70 85 N N ND
64 36 M - - - - 13.5 80 16 1 9 3.8 3 27 - 73 105 N N ND
65 54 M - - - - 11 96 28 1.1 9.3 4 3.2 29.7 - 70 76 N N ND
66 73 M - - + - 12.5 114 20 1 9.5 3.7 4 38 - 65 60.5 N N ND
67 27 F - - - - 13 110 24 0.9 8.9 4.9 3 26.7 - 58 100 N N ND
68 55 M - + - - 10 98 30 1.1 10 4.2 3.8 38 - 60 64 N N ND
69 47 M - - - - 12 80 28 1.1 9.8 4.6 3.7 36.26 - 58 68 N N ND
70 55 M - + - - 11 90 20 0.8 9 4.3 3 27 - 55 81 N N ND
71 58 F - - + + 9 96 18 1 9.5 4 4 38 - 65 65 N N ND
72 66 M - + - - 10.5 104 28 0.8 8.9 4.1 3.5 31.15 + 55 70 N N ND
73 53 M + - - - 13 114 16 0.9 8.6 4.5 3.7 31.8 - 60 80 N N ND
74 36 F - - - - 12 90 30 0.8 10 4.4 4 40 - 60 92 N N ND
75 41 M - - + - 13 80 26 0.7 9.5 4.2 3.5 33.25 - 58 110 N N ND
76 62 M - + - + 11.5 120 22 0.9 8.9 4 3 26.7 - 60 72 N N ND
77 65 F + - - - 10 130 28 0.9 9.2 3.8 3.5 32.2 + 65 64 N N ND
78 56 M - - + - 13 132 20 1.1 9.9 3.8 4 39.6 - 60 64 N N ND
79 45 F - - - - 8 98 18 0.8 9.4 4.6 2.8 26.3 - 62 102 N N ND
80 29 M - - - - 14 100 24 0.9 8.9 4.2 2.6 23.14 - 60 100 N N ND
81 58 M + + + - 12.3 104 28 1 10 4.6 3 30 + 70 79 N N ND
82 64 F - - - - 11 90 32 0.8 9.6 4 3 28.8 - 65 73 N N ND
83 50 M - - - - 13 116 20 1 10.3 3.9 3.4 34.1 - 58 72.5 N N ND
84 55 F - + + - 10 140 28 0.9 8.8 3.8 4 35.2 - 58 65 N N ND
85 44 F + - - - 11 128 18 1 8.2 4 3.8 31.16 - 60 68 N N ND
86 38 M - - - - 14.5 108 20 0.9 8.6 4.5 3 25.8 - 68 107 N N ND
87 68 M - + - - 10 80 20 1 8.8 4.1 4 35.2 - 65 65 N N ND
88 62 F - - - - 9 98 22 0.8 9.5 4.3 3.7 35.15 - 58 67 N N ND
89 56 M - + - - 12 128 30 0.8 9.6 4 3.5 33.6 - 50 73 N N ND
90 45 M - - - - 13.5 120 26 1.1 9 3.8 3.6 32.4 - 55 66 N N ND
91 61 M + - - - 13 90 20 1 10 4 3.8 38 - 63 69 N N ND
92 52 M - - - - 10 98 28 0.8 8.6 3.9 3 25.8 - 60 91 N N ND
93 35 F - - - - 12.5 140 28 0.9 8.8 4.6 3.2 28.16 - 58 80 N N ND
94 33 M - - - - 14 110 16 0.9 9 4 3 27 - 65 107 N N ND
95 42 F - - - - 11 94 22 1 9.5 3.8 3.5 33.25 - 63 73 N N ND
96 55 M - - - - 14 120 16 0.8 10 3.6 3 30 - 50 80 N N ND
97 54 F + + - - 12 104 28 0.8 8.8 3.8 3.5 29.4 + 58 73 N N ND
98 35 M - - - - 15 110 20 1 9 4 3 27 - 62 90 N N ND
99 54 M - - - + 11 120 30 1 9.4 4.1 3.4 31.96 - 60 70 N N ND
100 46 M + - - - 12.5 120 24 0.9 9.5 4.5 3 28.5 - 68 99 N N ND
